Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAMETIME-Mel
NCT06660420Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2025
- Primary completion
- Dec 2029
- Modality
- Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of SY-307 in melanoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
SY-307
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06660420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660420.